Key Highlights

  • HNGE third-quarter 2026 sales totaled $235.0 million, 52% above the $154.2 million of a year earlier.
  • Net income under GAAP was $57.4 million, equal to $0.66 per diluted share, reversing a prior year loss of $1.8 million, which equaled $0.02 a share.
  • The non-GAAP Operating Margin rose to 33% from 20%, while a 154% jump lifted non-GAAP Operating Income to $77.2 million.
  • A margin of 48% accompanied free Cash Flow of $112.7 million, up from $81.3 million in the same quarter last year.
  • Full-year 2026 Revenue projections now sit between $879 million and $881 million, implying roughly 50% growth at the center.

Stronger Member Yield Powers a Quarter Above Internal Guidance

Hinge Health (NYSE:HNGE) published its figures on Nov 2, 2026, covering the three months ended Sep 30, 2026. Top-line sales were $235.0 million, against $154.2 million previously, surpassing the $223 million to $225 million band management had projected. Leadership credited the excess entirely to billings, driven by higher yield, the share of qualifying members who sign up and stay active.

The company offers digital musculoskeletal care, plus migraine and gastrointestinal programs. Trailing-twelve-month billings, calculated, reached $960.3 million, up 54%, and the client roster expanded 28%, from 2,560 to 3,270.

Management traced the yield gain to focused enrollment pushes, which lifted new member joins by almost 75%, while renewals grew almost 25%.

Margin Expansion to 33% Turns a Year-Ago GAAP Loss Into Operating Profit

Non-GAAP gross margin climbed to 88% from 83%, while the GAAP figure improved to 87% from 82%, aided by reduced hardware expense and AI and automation. A 21% margin accompanied GAAP operating income of $50.3 million, following a $6.1 million operating loss a year before.

Non-GAAP operating income totaled $77.2 million, ahead of the $61 million to $63 million it had anticipated. Non-GAAP diluted EPS was $0.71, versus $0.32 a year earlier.

Operating costs as a share of sales dropped from 63% to 55%, management said. Operating Cash Flow grew to $114.6 million, up from $82.4 million.

Buybacks, a Cylinder Health Deal and Leadership Transition Shape Capital Use

Cash on hand plus marketable securities and restricted balances came to $358.5 million as of Sep 30, 2026. Roughly 296,000 shares were repurchased during the quarter, using $26 million, while M&A payments and net share settlements tied to employee stock vesting accounted for another $209 million.

The recent Cylinder Health Acquisition strengthened its gastrointestinal position. GI client numbers have expanded roughly 40% since the August announcement, musculoskeletal clients are up almost 30%, and the migraine client count is close to twice its level from last quarter.

The president's planned exit takes effect Jan 1, 2027, with a board appointment on Jan 4, 2027. Afterward, the chief commercial officer takes charge of the commercial team.

Upgraded Full-Year Targets Put Operating Margin Near 30% as GI Integration Nears

For the fourth quarter, the revenue range is $249 million to $251 million, around 46% growth at the center, and non-GAAP operating income reaches $81 million to $83 million. Full-year 2026 revenue guidance moved up to $879 million to $881 million, from a prior $856 million to $860 million range, while non-GAAP operating income guidance went to $266 million to $268 million, with a 30% margin at the center.

The yield projection for the full year has moved from 4.45% to 4.6%, alongside average eligible lives of roughly 25.5 million. The integrated GI program is slated for summer 2027, with significant revenue expected in 2028.